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Abstract
Background
The control or elimination of neglected tropical diseases (NTDs) has targets defined by the
WHO for 2020, reinforced by the 2012 London Declaration. We estimated the economic
impact to individuals of meeting these targets for human African trypanosomiasis, leprosy,
visceral leishmaniasis and Chagas disease, NTDs controlled or eliminated by innovative
and intensified disease management (IDM).
Methods
A systematic literature review identified information on productivity loss and out-of-pocket
payments (OPPs) related to these NTDs, which were combined with projections of the num-
ber of people suffering from each NTD, country and year for 2011–2020 and 2021–2030.
The ideal scenario in which the WHO’s 2020 targets are met was compared with a counter-
factual scenario that assumed the situation of 1990 stayed unaltered. Economic benefit
equaled the difference between the two scenarios. Values are reported in 2005 US$,
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006250 March 13, 2018 1 / 28
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Lenk EJ, Redekop WK, Luyendijk M,
Fitzpatrick C, Niessen L, Stolk WA, et al. (2018)
Socioeconomic benefit to individuals of achieving
2020 targets for four neglected tropical diseases
controlled/eliminated by innovative and intensified
disease management: Human African
trypanosomiasis, leprosy, visceral leishmaniasis,
Chagas disease. PLoS Negl Trop Dis 12(3):
e0006250. https://doi.org/10.1371/journal.
pntd.0006250
Editor: Christine M. Budke, Texas A&M University
College Station, UNITED STATES
Received: April 29, 2015
Accepted: January 18, 2018
Published: March 13, 2018
Copyright: © 2018 Lenk et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Prevalence cases
were calculated by the Department of Public Health
of Erasmus Medical Center, Rotterdam. The
contact person for these data is Sake de Vlas:
s.devlas@erasmusmc.nl. The sources of any other
relevant data are mentioned within the paper or are
publicly accessible sources, like the World Bank.
purchasing power parity-adjusted, discounted at 3% per annum from 2010. Probabilistic
sensitivity analyses were used to quantify the degree of uncertainty around the base-case
impact estimate.
Results
The total global productivity gained for the four IDM-NTDs was I$ 23.1 (I$ 15.9 –I$ 34.0) bil-
lion in 2011–2020 and I$ 35.9 (I$ 25.0 –I$ 51.9) billion in 2021–2030 (2.5th and 97.5th per-
centiles in brackets), corresponding to US$ 10.7 billion (US$ 7.4 –US$ 15.7) and US$ 16.6
billion (US$ 11.6 –US$ 24.0). Reduction in OPPs was I$ 14 billion (US$ 6.7 billion) and I$ 18
billion (US$ 10.4 billion) for the same periods.
Conclusions
We faced important limitations to our work, such as finding no OPPs for leprosy. We had to
combine limited data from various sources, heterogeneous background, and of variable
quality. Nevertheless, based on conservative assumptions and subsequent uncertainty
analyses, we estimate that the benefits of achieving the targets are considerable. Under
plausible scenarios, the economic benefits far exceed the necessary investments by
endemic country governments and their development partners. Given the higher frequency
of NTDs among the poorest households, these investments represent good value for
money in the effort to improve well-being, distribute the world’s prosperity more equitably
and reduce inequity.
Author summary
Human African trypanosomiasis, leprosy, visceral leishmaniasis and Chagas disease are
neglected tropical diseases (NTDs) controlled or eliminated by innovative and intensified
disease management (IDM). We estimated the economic impact of meeting the 2020 tar-
gets defined by the WHO for NTD control/elimination, reinforced by the 2012 London
Declaration. A systematic literature review identified information on productivity loss
and out-of-pocket payments (OPPs) relating to these NTDs. The economic benefit was
calculated by combining the estimated disease cases with estimated productivity losses
and OPPs resulting from the diseases, from the perspective of affected individuals. Very
little information about OPPs and productivity loss due to NTDs was found in the litera-
ture. The total global productivity gained by reaching the goals for the four IDM-NTDs
was I$ 23.1 billion in the period 2011–2020 and I$ 35.9 billion in the period 2021–2030.
The reduction in OPPs was I$ 14 billion and I$ 18 billion for the same periods. In order to
estimate the economic impact of meeting the London declaration targets regarding four
IDM-NTDs, we had to combine data from various sources, heterogeneous background,
and variable quality. Nevertheless, based on conservative assumptions and subsequent
uncertainty analyses, we estimate that the benefits of achieving the targets are nearly dou-
ble the required investments by endemic country governments and their development
partners to reach the 2020 targets.
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Introduction
Disadvantaged populations from low- and middle-income countries (LMICs) often have to
deal with the health and economic consequences of neglected tropical diseases (NTDs), which
can often aggravate their struggles to avoid poverty.[1–12] Chagas disease, human African
trypanosomiasis (HAT), leprosy and visceral leishmaniasis (VL) are still difficult and costly
to manage and available tools are unsuitable for use in large-scale preventive control pro-
grammes. They should be controlled or eliminated by “innovative and intensified disease
management” (IDM), as promoted by the World Health Organization (WHO). [13,14] The
populations affected by them frequently live in rural or remote areas, thereby limiting access to
diagnosis and treatment of both the disease as well as the disabilities they cause.[15]
Efforts of many private and public sector organizations have aimed at increasing the atten-
tion, as well as research and funding, given to NTDs. One of the results was the 2012 London
Declaration, based on targets set out in the WHO Roadmap for the control and elimination of
10 NTDs by the year 2020.[15–17]
Compared to studies of the epidemiology and health consequences of NTDs, relatively few
studies have examined the impact of NTDs on the productivity and out-of-pocket payments
(OPPs) of individuals, households, communities and countries.[18,19] There is clear evidence
that health improvements positively influence economic welfare and vice-versa. In this sense,
apart from addressing the human fundamental right to the highest attainable standard of
health, controlling and eliminating NTDs would also have a direct and sustainable effect on
the economic growth and financial welfare of the affected populations, and consequently lead
to greater national and global prosperity.[9,12,20–22]
Advances in understanding the economic consequences of NTDs could help to further
encourage prevention and control actions, assuring funders and policymakers that resources
committed to these efforts are a good investment, or at least resulting in increased health pol-
icy dialogue.[18,23]
We estimated the economic benefits of reaching the 2020 WHO targets for four IDM dis-
eases: Chagas disease, human African trypanosomiasis, leprosy and visceral leishmaniasis,
which meant estimating how much of the economic loss faced by affected individuals due to
productivity loss and out-of-pocket payments secondary to these diseases would be avoided by
reaching these targets.
Methods
General approach and study design
The general approach to estimate the economic benefits is the same as the one used to calculate
the benefits of achieving the 2020 WHO targets for NTDs controlled or eliminated by preven-
tive chemotherapy (PCT) described by Redekop et al. [24] This approach follows the concepts
used by Chu et al., and a conceptual framework can be seen as Supporting Information 1 (S1
Fig. Conceptual framework). [25]
The Global Burden of Disease Study (GBD) is the most extensive worldwide observational
epidemiological study up to now. Mortality and morbidity from major diseases, injuries and
risk factors to health are described at the global, national and regional levels. The GBD-2010
data of prevalent cases of the NTDs included in the London Declaration for the years 1990 and
2010 were used as starting points for the calculation of the estimates for other years. They were
obtained by interpolating between 1990 and 2010, as presented by de Vlas et al. The prevalent
cases until 2030 were estimated by extrapolation under the assumption that the 2020 WHO
Roadmap targets would be met and sustained beyond 2020. For each GBD disease sequela, a
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comparison is made between a counterfactual scenario (which assumed that the epidemiologi-
cal situation from 1990 regarding NTDs would continue unabated and that the number of
cases would increase as a function of overall population growth) and a target achievement sce-
nario (that considers the 2020 targets described in the 2012 London Declaration and described
by the WHO being achieved). [26]
We calculated the base case estimates of the benefit for the period between 2011 and 2030
(i.e., the period between ten years before and ten years after the target achievement) instead of
the entire period from 1990 to 2030. The economic benefit was calculated by subtracting the
costs for the target achievement scenario from the costs of the counterfactual scenario. The
economic benefit of each country was combined in order to provide region and global esti-
mates of the economic benefit.
International US$ (constant 2005 dollars) were used to express all estimates in this study. It
is a hypothetical unit of currency that has the same purchasing power as the U.S. dollar has in
the United States at a given point in time (in this case 2005). It is estimated using purchasing
power parity (PPP) exchange rate, defined as the amount of a country’s currency needed to
purchase the same amounts of goods and services in the domestic market as one U.S. dollar
would buy in the United States. It is a valid measure frequently used to compare estimates
between countries. [27,28]
Constant discounting at 3% was applied to both productivity loss and OPPs, using the base
year of 2010. Discounting is a mathematical operation to adjust future costs and effects of
health-care interventions to the “present value”. When calculating for discounting, for each
year (n) in the future the value of costs or benefits is multiplied by (1/(1 + D) n), D being the
discount rate. [24,29,30]
Following WHO’s recommendations, the economic benefits from prevented productivity
loss and out-of-pocket payments were reported separately. [23] All calculations were per-
formed using Microsoft Excel (version 2010). [31]
Perspective
Like previous NTD economic impact studies, we used the human capital approach in our
study with the perspective of the individual affected by an NTD to analyze the economic costs
per GBD sequela, sex and country.
The WHO Guide to Identifying the Economic Consequences of Disease and Injury distin-
guishes the following cost categories when calculating the microeconomic impact of disease
and injury: expenditures on health; labour and productivity losses; effects on human, physical
and financial capital formation; non-market impacts such as leisure or caregiver time. We only
included the first two in our analyses, incurred by affected individuals during illness in low-
and middle-income countries. [23,32–35]
Countries
All countries referred by the GBD study as endemic for IDM NTDs were included in the anal-
yses [23]. The list of countries per disease can be found using the open-access web-based dis-
semination tool available at https://erasmusmcmgz.shinyapps.io/dissemination/.
Literature review
We performed a systematic review of the literature to identify general and country-specific
information on productivity loss (indirect labor costs resulting from reduced working hours
and economic activity attributable to morbidity) and direct costs incurred by individuals (such
as consultation fees, medication, transport, food, assistance, accommodation) due to the 10
Socioeconomic benefit of achieving the 2020 targets for IDM NTDs
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006250 March 13, 2018 4 / 28
NTDs included in the London Declaration. Although in this paper we report on four IDM
NTDs, we combined the 10 NTDs in the review, since many papers often refer to several
NTDs and describe the economic impact of the related sequelae. Details about the methodol-
ogy applied to all NTDs and the results regarding the findings on productivity loss related to
the NTDs eligible for PC can be found in the review by Lenk et al.[36] In summary, the
searched databases included Embase, Medline (OvidSp), Web of Science, Scopus, CINAHL,
PubMed publisher, Cochrane, Popline, Lilacs, Scielo and Google Scholar. Websites of relevant
organizations (i.e. World Health Organization, the Centre for Neglected Tropical Diseases, the
Carter Center) were also screened for relevant grey literature. The search syntax used for each
database can be found in the Supporting Information (S1 File. Literature Search Syntax), and
the complete list of institutions searched for grey literature can be found in Supporting Infor-
mation 3 (S2 File. Grey Literature Search). A total of 11,449 articles concerning all 10 NTDs
were identified using the database searches. Of these, 5,316 articles remained after duplicates
were removed (S1 Table. Results of database searches). We sorted the articles that were related
to each particular disease and screened the abstract and title of all papers, examining the full-
text version of all articles that provided information on productivity loss or indirect costs. The
paucity of studies that provide quantitative estimates of productivity loss and OPPs from
NTDs can be seen in Supporting Information 5 (S2 Table. Literature review—results per dis-
ease). [36]
Productivity loss
The formula below was used to calculate the annual productivity loss for each NTD and coun-
try, using the prevalence estimates for the counterfactual and target achievement scenarios
independently (Fig 1).
Prevalent cases
We used the estimates relative to both the counterfactual and the target achievement scenarios
calculated by de Vlas et al, as described in the general approach. [26] The population older
than 15 years was used for the calculation of productivity loss. [24]
Productivity loss from disease manifestations
Disease can lead to productivity loss in many ways, including reduced productivity at work
(presenteeism), absence from work (absenteeism) or even job loss, which were translated into
each infected individual’s annual loss of income due to the effects of each NTD sequela.
[23,25]
Unless otherwise specified, we converted the least biased value of productivity loss found in
the literature into annual percentages per sequela, assuming 300 working days per year, as
seen in Table 1. [25] In every year of the interval we assumed that there were no differences in
Fig 1. General formula for calculating productivity loss. TPC = Total productivity costs (in US$ 2005), NTD = Neglected Tropical Disease,
c = Country, y = Year, PS1 = Number of prevalent cases aged 15+ years with sequela 1, PS2 = Number of prevalent cases aged 15+ years with sequela
2, PLs1 = % productivity loss related to sequela 1 of NTD, PLs2 = % productivity loss related to sequela 2 of NTD, I = GDP per capita in the lowest
quintile, D = Annual discount rate, t = Time (years beyond 2010).
https://doi.org/10.1371/journal.pntd.0006250.g001
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productivity loss between men and women, between younger and older persons, and between
countries. We also assumed that all persons older than 15 years are equally productive. If no
estimates for productivity loss were found in the literature, assumptions were made as
described in Table 1.
Table 1 shows the estimates of annual productivity loss for each sequela included in the
GBD study for IDM NTDs. Sequelae related to poor mental illness due to IDM diseases were
not included in the GBD study and cutaneous leishmaniasis is not included in the London
Declaration. Please refer to S3 Table. Publications reporting productivity loss for Chagas Dis-
ease and S4 Table. Publications reporting productivity loss for Visceral Leishmaniasis for a
more detailed description of the sources. It shows mostly the productivity loss from absentee-
ism, due to lack of data on presenteeism. The table also shows additional information for
Table 1. Annual percentages of productivity loss used in the calculations of economic benefit.
Disease & Sequela Severity Base case—Annual
productivity loss1
Case
Mix2
Source Remarks
Chagas
Acute 2.33% N.A. [37] 7 of 300 working days
Chronic heart disease 4.67% N.A. [37] 14 of 300 working days
Chronic digestive
disease
Normal bowel
function
0% 30% [37,38] 1% of the individuals with abnormal bowel function are assumed to undergo
surgery, with a productivity loss of 45% (135 days of 100% productivity loss).
Weighted average of prod loss of 3.8%.Abnormal bowel
function
5% 70% [37,39]
Heart failure Mild 0% 10% [37,40] 14/300 working days and disability weight. Weighted average of prod loss of
61%.Moderate 4% 30%
Severe 100% 60%
Human African trypanosomiasis
Cognitive
impairment
Severe 100% (Assumption) 52.5%4 7 Weighted average of productivity loss of 57%.4
Disfigurement Level 2 10%3 47.5%4 7
Leprosy
Disfigurement due
to leprosy
Level 2 28% N.A. [41]
Visceral leishmaniasis
Visceral
leishmaniasis
100% (if untreated)5 N.A. [42–
45]
Country-specific values were used to reflect differences in diagnosis and/or
treatment patterns.
6–30% (if treated)6
N.A.–Not applicable
1. If the original source did not provide the percentage of productivity loss, this was calculated based on the measurement unit used in the original source.
2. The case mix represents the distribution of the different degrees of severity within a disease sequela. Since the prevalent case estimates were only available per disease
sequela and not severity, for sequelae with heterogeneous levels of severity (i.e., mix of milder and more severe forms), the productivity loss values (of the different
degrees of severity) were combined with the case mix frequency to calculate a frequency-weighted value of productivity loss for that sequela. For sequelae with a more
homogeneous level of severity, the productivity loss value was applied to all prevalent cases.
3. Used the same as onchocerciasis moderate skin disease [46].
4. The case mix in 2010 consisted of 47.5% mild cases and 52.5% severe cases, which changed linearly to 100% mild cases and 0% severe cases in 2020. Consequently, the
weighted productivity loss of 57% in 2010 decreased linearly to 10% in 2020, which was represented solely by the productivity loss due to mild cases.”.
5. The global estimate for the productivity loss of untreated patients is 50% (assuming 100% productivity loss over duration of illness, and assumed duration from
symptoms to death is 6 months).
6. Productivity loss for treated patients in India, Sudan, Bangladesh, and Nepal is 20%, 30%, 6% and 20% respectively, which was extrapolated to the respective WHO
region.
7. Case-mix values from the GBD study documentation and from the assumptions used by de Vlas et al.
https://doi.org/10.1371/journal.pntd.0006250.t001
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chronic digestive disease and heart failure due to Chagas disease since the GBD study only
reported the number of cases per disease sequela and not according to severity level. For exam-
ple, regarding heart disease, only the numbers of cases with heart disease were reported and
not the numbers per severity level (i.e. mild, moderate, severe). Therefore, in order to calculate
an overall estimate of productivity loss, we had to combine our estimates of productivity loss
per severity level with the estimated frequencies of the different severity levels (i.e., the ‘case
mix’). Table 1 therefore shows the productivity loss according to severity and case mix regard-
ing severity for chronic digestive disease and heart failure. Upper and lower limits for the esti-
mates of productivity loss are shown in the sensitivity analysis section.
Productivity loss due to premature mortality
The number of productive years lost due to NTD-related premature mortality per person was
estimated using the country-, age-, and sex-specific data on years-of-life lost (YLL) as provided
by the GBD study. The GBD calculations used uniform Japanese life-expectancies attributed to
the year of death, but for our study we preferred to use country-specific life expectancies and
only for the study period 1990–2030. We have therefore divided the YLL values by the Japa-
nese age-specific life-expectancies to arrive at the number of deaths per country, age and sex,
and treated them as incident cases for ‘absent persons’ due to death by an NTD (e.g., visceral
leishmaniasis). The prevalence of such ‘absent persons’ was then calculated similar to the pro-
cedure for irreversible disease manifestations. Work-years lost were now calculated by the dif-
ference between the number of absent persons for the counterfactual scenario and target
achievement scenario over the 1990–2030 period. Economic benefit from averted premature
mortality in the 2011–2030 period was calculated by combining the lost productive years with
income per person, for the 15+ age group. Discounting at 3% was applied to the results using
the base year of 2010. [24]
Income
IDM-NTDs are highly prevalent in countries that are no longer regarded as low-income coun-
tries. Nevertheless, most NTDs continue to affect poor populations that do not experience the
welfare and health benefits of the economic growth seen in these countries. [47,48]
Different methods were applied in previous economic analyses of NTDs to estimate the
rural wage, including use of GDP per capita, average agricultural value added per worker and
the lowest wage estimate from distinct predefined wage sources. [37,38,40]
We compared the GDP per capita of the lowest income quintile with the minimum nomi-
nal annual wage (both 2010 PPP) for the endemic countries with the highest number of preva-
lent cases (which would have the highest impact on the final results) and found that the
minimum wage was higher than the GDP per capita of the lowest income quintile. Consider-
ing the characteristics of the populations affected by NTDs regarding welfare mentioned
above, we decided to use the GDP per capita of the lowest income quintile as a proxy for
income when calculating the base-case impact estimate, and use only one data source for
income instead of several.
GDP per capita for each country (purchase power parity-PPP, 2005 international $) and
income shares of the five income quintiles were obtained from the World Development Indi-
cators of the World Bank’s website.[49] In the rare cases where information about GDP per
capita or income shares of the year 2010 for a country was lacking, we used data from previous
years; if no information from any year was available, we used the average of surrounding
countries.
Socioeconomic benefit of achieving the 2020 targets for IDM NTDs
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Since many of the countries included in this study have shown an increase in the GDP per
capita of the lowest quintile in the last decade, we assumed that the income shares and the
GDP per capita remained constant over the assessed period of 2011–2030, to keep estimates
conservative. Income was not adjusted for labor force participation (people employed or
actively looking for work) or age-related income patterns.
Out-of-pocket payments (OPPs)
The annual economic burden related to out-of-pocket payments was calculated using the for-
mula below for each country and NTD independently (Fig 2). Despite the limited number of
studies of OPPs from IDM-NTDs, it was possible to use country-specific values for Brazil,
Argentina and Mexico, currently the countries with the highest prevalence of Chagas disease
(based on GBD estimates). Their values for OPPs and productivity loss were therefore calcu-
lated separately. They serve as examples of how the economic impact of Chagas disease could
be calculated for each country, if sufficient country-specific data are available.
Costs were calculated by multiplying four values: the total number of cases in each year;
annual direct costs per sequela; percentage of cases treated each year, and percentage of
patients paying for treatment each year. Since OPPs are not related to the ability to work, they
were calculated for all prevalent cases, including children. We assumed no change in prices for
the period 2011–2030 to keep estimates conservative.
Prevalence estimates
The same prevalence estimates used to calculate the productivity loss were used to calculate
the OPPs.
Annual out-of-pocket payments
OPPs relate to expenses usually incurred by an affected individual due to the illness, including
consultation fees, medication, diagnostic tests, travel and escort costs, food, accommodation,
etc. Whenever the information was available, the cost of the drug was excluded from the OPPs
in case it is donated for free or reimbursed, as well as consultation or laboratory exams if they
are also covered by the local health system. Depending on the data identified in the literature,
country- or region-specific values were used. The same treatment value per sequela was used
for all individuals in each country and sequela, and prices were adjusted to 2005 values using
Consumer Price Index (CPI) and purchase power parity (PPP).[49]
In our calculations, the amount paid by patients varied depending on which direct costs
patients have to pay per disease sequela and country. OPPs for HAT, for instance, included
consultation fees, cost of travel, laboratory costs, all expenses for hospitalization as well as food
for the patient and the caregiver. If the OPP described in the literature did not include non-
medical payments, since estimates for these costs were lacking in the literature, we opted not
Fig 2. General formula for calculating out-of-pocket payments. TDC = Total out-of-pocket payments (in US$ 2005),
NTD = Neglected tropical disease, c = Country, y = Year, PS1 = Number of persons with sequela 1 of NTD, PS2 = Number of persons
with sequela 2 of NTD, DCS1 = Annual out-of-pocket payments relating to sequela 1 (per WHO region or country), DCS2 = Annual
out-of-pocket payments relating to sequela 2 (per WHO region or country), PT = Percentage of patients treated, PP = Percentage of
patients paying for the treatment, D = Annual discount rate, t = Time (years).
https://doi.org/10.1371/journal.pntd.0006250.g002
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to include them, also to keep our results conservative. If the medication was not included in
the list of reimbursed drugs or the NTD was not included in the health insurance package, we
assumed that all patients had to pay for treatment. This was the case for the three countries for
which we could find specific information in the literature about Chagas disease. [38,50–68]
Percentage of cases treated and paying for treatment
The Sustainable Development Goals (SDGs) emphasize the need to address inequity and pro-
vide health for all. The goal of universal health coverage (UHC) means financial risk protec-
tion, access to quality healthcare services, and access to safe, effective, quality, and affordable
essential medicines and vaccines for all. [69] In line with these concepts, a joint WHO/World
Bank framework for monitoring progress towards UHC proposed a target of a minimum of
80% essential health services coverage and 100% financial protection from out-of-pocket pay-
ments in 2030, which would mean 100% of the population at risk protected against out-of-
pocket payments due to NTDs by 2030. [70]
Parallel to the assumption that the London Declaration targets would be met, we therefore
assumed a scenario where 80% of health coverage and 100% of financial protection would be
achieved in 2030, instead of only assuming that people seeking care ‘do not suffer financial
hardship when using health services.’ [71] We assumed that the percentage of patients cur-
rently paying for the treatment corresponds to the percentage of persons not covered by health
systems or insurance, since, by definition, out-of-pocket payments are direct payments made
by individuals to healthcare providers at the time of service use. [72]
In the counterfactual scenario, the percentage of cases that were treated in 2010 was kept
constant at that level until 2030, to simulate a situation where nothing would be done. Simi-
larly, the percentage of cases that paid for their treatment in 2010 was kept constant until 2030.
In the target achievement scenario, we assumed that the percentage of cases treated in 2010
would linearly increase to 80% in 2030, and we assumed that the percentage of patients who
paid for their treatment in 2010 would linearly decrease to 0% in 2030.
For these percentages, the literature review provided country-specific data for the three
most prevalent countries for Chagas disease: Argentina, Brazil and Mexico. [38,53,56,58,60–
65,73–75] A general average price for Latin America from Wilson et al was used for all other
endemic countries, after correction for PPP for each endemic country (Table 2). [51]
Like Chagas, some country-specific OPPs for visceral leishmaniasis were found for India,
Bangladesh, Nepal, and Sudan, which were used to calculate the annual OPPs for these coun-
tries (sources listed in S5 Table. Publications reporting Out-of-Pocket Payments for Chagas
disease and S6 Table. Publications reporting Out-of-Pocket Payments for Visceral Leishmania-
sis). A general average price available from the literature was used for all other endemic coun-
tries. Percentages for treated patients (successfully and unsuccessfully), untreated patients and
patients paying for treatment were also derived from the literature and were assumed to line-
arly reach 80% treatment (keeping the same proportion between the three treatment catego-
ries) and 100% not paying for treatment in 2030, considering UHC as previously mentioned
(Table 3).
All drugs currently used for the treatment of human African trypanosomiasis are donated
to WHO for free distribution by the manufacturers (Sanofi and Bayer). Nevertheless, individu-
als affected by HAT still bear other costs than medication costs when seeking treatment, which
is one of the reasons for many of them either not to seek treatment, or only do so long after
their diagnosis or when their symptoms become more acute. [91] The OPPs described for
HAT in the study by Lutumba et al. included these costs, i.e consultation fees, cost of travel,
laboratory/diagnostic costs, food for the patient and caregiver during hospitalization, and
Socioeconomic benefit of achieving the 2020 targets for IDM NTDs
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material such as syringes and needles. These costs were used for all endemic countries, after
correction (Consumer Price Index—CPI and purchase power parity—PPP (Table 4). [27,91–
93].
We assumed no OPPs for leprosy since no information was available from the literature at
the time the literature review was performed and to keep the estimates of OPP conservative.
This assumption is supported by the fact that multidrug therapy (MDT) has been made avail-
able free of charge through the WHO for the past 20 years. The costs of palliative treatment of
the incurable sequelae were not included for the same reasons.[70]
Return on investment
We calculated the net return on investment (ROI) by obtaining a crude estimate of the rela-
tionship between the economic benefit and the necessary investments to reach the 2020 NTD
Table 2. Out-of-pocket payments, percentage of patients being treated and percentage of patients paying for treatment according to the literature, used in the cal-
culations for Chagas disease (I$—International dollars).
Out-of-pocket payments
Acute Chronic Heart Disease Chronic Digestive Disease Heart failure Source
Argentina $ 32.35 $ 3,505.46 $ 4,275.12 $ 3,505.46 [37,76]
Brazil No costs $ 2,574.21 $ 902.71 $ 8,231.06 [56,58]
Mexico $ 112.54 $ 267.69 $ 875.90 $ 19,351.39 [68]
General 1 $ 15.98–46.94 $ 390.1–1115.83 $ 390.1–1115.83 $ 296.2–1564.03 [38,51]
Percentage being treated
All countries 10% 35% 35% 35% [38,39,51]
Percentage paying for treatment
Argentina 100% 38% 38% 38% [54,55,57,77,78]
Brazil 0% 25% 25% 25% [57,79,80]
Mexico 100% 100% 100% 100% [50,57,81,82]
General 2 100% 25% 25% 25% [57,79,80]
1. Between country variation
2. For conservative reasons, we assumed the same situation as in Brazil for all other endemic countries, since Brazil has the lowest percentage of people paying: 75% of
the population has free access to its health system. [79]
https://doi.org/10.1371/journal.pntd.0006250.t002
Table 3. Values used to calculate out-of-pocket payments (OPPs) for visceral leishmaniasis (I$—International
dollars).
Out-of-pocket payments Reference
India $ 354.75 [43]
Sudan $ 488.89 [43,83,84]
Bangladesh $ 286.84 [45]
Nepal $ 364.00 [42]
General $ 160.00 [84,85]
Percentage being treated
India 80% [86–88]
Sudan
treated successfully 50% [89]
treated unsuccessfully 5%
untreated (undetected) 45%
Nepal/Bangladesh 80% [87,90]
https://doi.org/10.1371/journal.pntd.0006250.t003
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Roadmap targets and the 2030 SDG targets. The net ROI is the current value of the benefit to
affected individuals minus the current value of the cost to public and philanthropic funders,
divided by the current value of the cost to public and philanthropic funders. The economic
benefit to affected individuals of averted OPP and productivity loss calculated in this study
and the investment costs based on recent WHO estimates published in the Third Report on
Neglected Tropical Diseases were used in these calculations.
In the case of IDM NTDs, only investments in individual management of HAT, leprosy,
and visceral leishmaniasis were included, as well as active case finding for HAT, leprosy and
VL, and vector control for VL (only in areas of the Indian subcontinent that are not co-
endemic with malaria), plus the cost of integrated surveillance in HAT-endemic areas. Invest-
ments and benefits related to Chagas disease were not included. [70]
For comparison to the disease-specific investment targets published by WHO in the Third
Report on Neglected Tropical Diseases, the I$ 2010 benefits were converted to US$ 2015. Since
part of these benefits can clearly be credited to investments made before 2011, we conserva-
tively assumed the investments to be equal to those in 2011 (adjusted for inflation). We
assumed 1990 to mark the beginning of concerted global efforts to control most NTDs and
2011 to mark the beginning of the recent scale-up in investment to eliminate them. In reality,
investments before 2011 were probably lower than this in most countries. We did not consider
investments in improving housing and water and sanitation that occurred over the same
period, since these were not targeted at the NTDs but contributed to their control nonetheless.
The ROI for middle and low income settings was not calculated separately due to lack of the
necessary data on investments. Since investments estimates are given in US$, ROI is presented
in US$ only. A discount rate of 3% per annum was applied for both costs and benefits. More
detailed information on the ROI and the internal rate of return per WHO region, as well as
other considerations on the investment case of ending/controlling NTD, can be found in the
recently published DCP3/World Bank volume on infectious diseases by Fitzpatrick et al. [95]
Sensitivity analysis
The economic benefit was calculated using base-case values for the components of the formu-
lae described above. We examined how much effect changes in four input parameters used in
our calculations had on the estimated economic benefit: 1) the prevalence estimates, 2) the
productivity loss percentages and out-of-pocket payments, 3) income, and 4) percentage of
patients seeking and paying for treatment.
We performed a probabilistic sensitivity analysis, where the values of all input parameters
are varied simultaneously to obtain the overall uncertainty regarding the economic benefit.
Beta PERT distributions were used in combination with values shown in Table 5; the values of
the different parameters were assumed to be independent of each other.
By applying the country-specific upper and lower confidence limits of the GBD—2010 esti-
mates, we examined the relevance of uncertainty about the prevalence in all the years in the
Table 4. Values used to calculate out-of-pocket payments (OPPs) for human African trypanosomiasis (I$—Inter-
national dollars).
OPPs Reference
Annual prices per HAT case $ 156.77 [91]
Percentage being treated
General 24% [94] (7,200 reported, 30,000 estimated)
Patients paying
General 100% Assumption
https://doi.org/10.1371/journal.pntd.0006250.t004
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2010–2030 period. Productivity loss and OPP values were varied by using the highest and low-
est values found in articles with sufficient quality retrieved in the literature review. If no esti-
mates were available from the literature, assumptions were made, as described in Table 1. For
each disease, we varied income using data from the country with the most prevalent cases in
the world. The lower limit of income equalled the average income in the lowest income decile
in that country, while the upper limit equalled the average income in the second-lowest
income quintile. For OPPs, we varied the uncertainty regarding out-of-pocket payments (per
person) by a factor of 2 (i.e., from 50% to 200%). [24]
The rough estimates of the return on investment calculated in this study were not subject to
sensitivity analysis, following the original publication by Fitzpatrick et al. [95].
Technical validity
R scripts were written to examine the technical validity of our Excel-based calculations. They
used the same original data (GBD, UNPOP (United Nations Population Division), GDP, pro-
ductivity loss) as the Excel files (though transformed), but were completely independent of the
Excel calculations. The small number of differences were found led to the improvement of the
formulae for some of the diseases and subsequent matching (or calibration) of the results,
although the general programming in Excel did not change. R scripts and sample Excel sheets
can be found in the Supporting Information section.
Table 5. Upper and lower limits used in the sensitivity analyses.
Chagas disease HAT Leprosy Visceral leishmaniasis
Lower
limit
Point
estimate
Upper
limit
Lower
limit
Point
estimate
Upper
limit
Lower
limit
Point
estimate
Upper
limit
Lower
limit
Point
estimate
Upper
limit
Relative uncertainty in
global prevalence in 2010
0.226 1.000 1.90 0.190 1.000 2.90 0.689 1.000 1.41 0.569 1.000 1.57
Estimates of productivity
loss 1
50% 57% 100% 2% 5% 10% 14% 28% 55% 6% 19% 100%
Estimates of income 0.836 1.000 1.673 0.588 1.000 2.265 0.871 1.000 1.424 0.871 1.000 1.424
Out-of-Pocket Payments
per person
0.50 1.00 2.00 115 700 11,954 N.A.6 N.A. 6 N.A. 6 1.00 1.00 1.00
Probability of being treated
(counterfactual scenario)
0% 6.7% 2
35% 3,4,5
100% 0% 24% 100% N.A. 6 N.A. 6 N.A. 6 0% 55% 100%
Probability of paying for
healthcare
(counterfactual scenario)
0% 67% 2
69.4% 3,4
34.2% 5
100% 0% 80% 100% N.A. 6 N.A. 6 N.A. 6 0% 80% 100%
Probability of being treated
(target achievement
scenario)
0% 80 2 3,4,5 100% 0% 80% 100% N.A. 6 N.A. 6 N.A. 6 0% 80% 100%
Probability of paying for
healthcare
(target achievement
scenario)
0% 0% 100% 0% 0% 100% N.A. 6 N.A. 6 N.A. 6 0% 0% 100%
1. The productivity loss estimates seen in Table 1 are here shown as frequency-weighted estimates per disease with their respective upper and lower limits used in the
sensitivity analysis
2. Value for acute Chagas disease sequela (weighted average of three most prevalent countries).
3. Value for chronic heart disease sequela (weighted average of three most prevalent countries).
4. Value for chronic digestive disease sequela (weighted average of three most prevalent countries).
5. Value for heart failure sequela (weighted average of three most prevalent countries).
6. N.A.–not applicable
https://doi.org/10.1371/journal.pntd.0006250.t005
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The health benefits calculated by De Vlas et al. and the economic benefits shown here will
be publicly available through the open access website: https://erasmusmcmgz.shinyapps.io/
dissemination/.
Results
Productivity loss
Fig 3 provides a graphical demonstration of the different cost estimates and their trend over
time in the counterfactual and target achievement scenarios. The difference between the rising
productivity costs in the counterfactual scenario and the decreasing costs in the target achieve-
ment scenario represents the total economic benefit of achieving the targets, which is highly
dependent on the estimated prevalence of the IDM-NTDs over time. Since the same pattern
can be seen for all IDM diseases and related sequelae, we provide the example of productivity
costs from the Chagas chronic heart disease sequela (the sequela with the biggest impact).
Overview of the global estimates of the economic benefit from averted
productivity loss
Table 6 shows the total economic benefits in productivity gain for each of the IDM-NTDs and
their sequelae. The total benefits of achieving the targets for all four IDM diseases were esti-
mated at I$ 23.1 billion (I$ 15.9–34.0 billion) or US$ 10.7 billion (US$ 7.4–15.7 billion) in
2011–2020 and I$ 35.9 billion (I$ 25.0–51.9 billion) or US$ 16.6 billion (US$ 11.6–24.0 billion)
dollars in 2021–2030 (base case estimates and 2.5th and 97.5th percentile values from the sensi-
tivity analysis).
Fig 3. Productivity loss due to Chagas chronic heart disease according to the counterfactual and target achievement scenarios (millions I$
—International dollars). Total global loss per year in the counterfactual scenario (blue) and target achievement scenario (orange). The
economic benefit is the difference between both scenarios.
https://doi.org/10.1371/journal.pntd.0006250.g003
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Fig 4 shows the total values per disease (in I$) together with the sensitivity analysis diagram
of the calculations of the total economic benefit of achieving the 2020 targets for the IDM dis-
eases. The total economic benefit calculated for the entire period was $59.0 billion, with the
2.5th and 97.5th percentile values of I$ 40.9 and I$ 85.9 billion calculated in the sensitivity
analysis.
Fig 5 shows the regional variation in the economic benefit, with the Americas and South-
East Asia outweighing over the other regions due to Chagas disease and visceral leishmaniasis,
respectively. More productivity loss prevented can be expected in the Americas and South-
East Asia regions due to Chagas disease and visceral leishmaniasis, respectively.
Out-of-pocket payments
IDM-NTDs impose a considerable burden on patients, mostly due to their incurable sequelae,
and often compel patients to seek and pay for treatment. [13,96] Table 7 shows the economic
gains regarding out-of-pocket payments that could be expected by reaching the 2020 targets
for IDM-NTDs. Chagas chronic heart disease is the main reason for the OPPs among all
sequelae.
Fig 6 shows the total values per disease together with the sensitivity analysis diagram. The
total economic benefit calculated for the entire period was I$ 33 billion, with the 2.5th and
97.5th percentile values of I$ 5 and I$ 90 billion calculated in the sensitivity analysis.
Return on investment
The ROI was calculated based on an estimated benefit of US$ 5.4 billion (in 2015–2020) and
US$ 20.9 billion (in 2015–2030), assuming the 2020 targets for IDM diseases were to be met,
and considering costs to funders of US$ 1.1 billion and US$ 2.2 billion in 2015–2020 and
2015–2030, respectively.
The net benefit was estimated to be US$ 0.9 [0.62–1.32] for every dollar invested during the
period 1990–2020 and US$ 2.8 [1.94–4.05] for every dollar invested in the period 1990–2030
Table 6. Total economic benefit from productivity loss averted, base case estimates and 2.5th and 97.5th percentiles (billions I$—International dollars and US$—US
dollars 3% discounting from 2010).
Disease Sequelae Economic benefit (productivity loss averted) I$
—International dollars
Economic benefit (productivity loss averted)
US$—US dollars
2011–2020 2021–2030 2011–2020 2021–2030
Chagas disease Acute $ 0.4 $ 0.5 $ 0.2 $ 0.3
Chronic heart disease $ 5.1 $ 7.9 $ 2.9 $ 4.6
Chronic digestive disease $ 0.8 $ 1.1 $ 0.5 $ 0.6
Heart failure $ 0.3 $ 0.8 $ 0.2 $ 0.5
Chagas deaths $ 1.6 $ 2.7 $ 0.9 $ 1.5
Total $ 8.2 [3.0–17.2] $ 13.0 [4.9–27.6] $ 4.7 [1.7–9.8] $ 7.5 [2.83–15.9]
HAT African trypanosomiasis $ 0.5 $ 0.6 $ 0.3 $ 0.3
African trypanosomiasis deaths $ 2.7 $ 4.1 $ 1.5 $ 2.3
Total $ 3.2 [2.6–16.6] $ 4.7 [1.5–9.8] $ 1.8 [1.5–9.3] $ 2.6 [0.9–5.5]
Leprosy Disfigurement $ 3.7 $ 5.0 $ 1.5 $ 2.0
Total $ 3.7 [2.0–6.2] $ 5.0 [2.7–8.4] $ 1.5 [0.8–2.5] $ 2.0 [1.1–3.4]
Visceral leishmaniasis Visceral leishmaniasis $ 0.1 $ 0.1 $ 0.03 $ 0.04
Visceral leishmaniasis deaths $ 7.9 $ 13.2 $ 2.7 $ 4.5
Total $ 8.0 [5.1–11.7] $ 13.3 [8.5–19.4] $ 2.7 [1.7–3.9] $ 4.5 [2.9–6.6]
Total (all diseases) $ 23.1 [15.9–34.0] $ 35.9 [25.0–51.9] $ 10.7 [7.4–15.7] $ 16.6 [11.6–24.0]
https://doi.org/10.1371/journal.pntd.0006250.t006
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(best estimates and 2.5th and 97.5th percentiles related only to the benefits). A net benefit of US
$ 0.9 per dollar means every dollar invested yielded US$ 1.9 in benefits, or benefits nearly dou-
ble the investment in the period 1990–2020. [95]
Discussion
This study is a first attempt to estimate the global economic benefits of achieving the London
declaration targets for four IDM NTDs (Chagas disease, human African trypanosomiasis, lep-
rosy, and visceral leishmaniasis).
General approach
Scarce and heterogeneous data available on country- or regional-specific productivity loss and
OPPs related to the different NTDs and their sequelae limits the comprehensiveness of this
economic analysis to some extent. The same can be said about the paucity of information
regarding the characteristics of the affected populations (e.g. income) and the impact of
assumptions regarding the future frequencies of each NTD. More accurate measures of pro-
ductivity loss caused by NTDs and better descriptions of the affected populations (e.g., type of
Fig 4. Global economic benefit (productivity loss averted) for IDM NTDs, for the period 2011–2030 (billions I$—International dollars).
Global economic benefit from reaching the targets for IDM NTDs, lower and upper estimates from sensitivity analysis. Global economic benefit
per disease.
https://doi.org/10.1371/journal.pntd.0006250.g004
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work, income) in the different affected countries would greatly improve the quality of any esti-
mates of the economic burden of NTDs and the economic benefits of controlling NTDs.
The economic benefits of reaching the 2020 targets for IDM-NTDs were estimated using
the human capital approach, which increases comparability with other studies. However, crit-
ics may argue that it overestimates the extent of productivity loss from the societal perspective.
[97] Nevertheless, the perspective from the individuals affected by these diseases, rather than a
societal one, was chosen for this study. The first reason for this choice was to maintain compa-
rability with the recently published results regarding the economic benefit of reaching the
2020 London Declaration targets for PCT NTDs (i.e., the ones controlled or eliminated
Fig 5. Regional economic benefit (productivity loss averted) for IDM NTDs, for the period 2011–2030 (billions I$—International dollars)
per WHO region. Regional economic benefit from reaching the targets for IDM NTDs, for the period 2011–2030 per WHO region.
https://doi.org/10.1371/journal.pntd.0006250.g005
Table 7. Total economic benefit from out-of-pocket payments averted, base case estimates and 2.5th and 97.5th percentiles (billions I$—International dollars and
US$—US dollars) discounting 3% from 2010.
Disease Sequelae Economic benefit (OPPs averted) I$—
International dollars
Economic benefit (OPPs averted) US$—US dollars
2011–2020 2021–2030 2011–2020 2021–2030
Chagas disease Acute $ 0.02 $ 0.05 $ 0.01 $ 0.03
Chronic heart disease $ 12.52 $ 14.50 $ 5.70 $ 8.20
Chronic digestive disease $ 1.41 $ 2.95 $ 0.81 $ 1.74
Heart failure $ 0.15 $ 0.48 $ 0.08 $ 0.26
Total $ 14.10 [2.2–41.7] $ 17.97 [2.5–48.6] $ 6.57 [1.2–21.9] $ 10.24 [1.3–25.5]
HAT African trypanosomiasis $ 0.19 [0.001–1.5] $ 0.20 [0.001–1.6] $ 0.10 [0.0005–0.75] $ 0.10 [0.0005–0.80]
Visceral leishmaniasis Visceral leishmaniasis $ 0.13 [0.06–0.19] $ 0.14 [0.06–0.22] $ 0.05 [0.02–0.07] $ 0.05 [0.02–0.08]
Total (all diseases) $ 14.42 [2.4–42.0] $ 18.31 [2.6–48.9] $ 6.72 [1.12–19.55] $ 10.39 [1.48–27.75]
https://doi.org/10.1371/journal.pntd.0006250.t007
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through preventive chemotherapy).[24] Secondly, the friction cost method focuses only on
lost productivity until a replacement can be found. Use of the friction cost method is likely to
have a limited effect on the results for leprosy and Chagas since these diseases can lead to
reduced productivity while working (presenteeism) rather than simply lost work days (absen-
teeism) and presenteeism will not necessarily lead to replacement of the worker. Therefore, the
use of the friction method is not expected to have a substantial effect on the estimated eco-
nomic benefit for these diseases. In contrast, the biggest economic impact for HAT and VL is
through avoiding premature deaths. Therefore, the friction cost method might have been a
better choice, since premature death would lead to worker replacement. We also acknowledge
that the aggregation of individual costs does not exactly correspond to the total societal cost,
since individuals’ productivity losses can be compensated by a variety of mechanisms at the
societal level. Some of these mechanisms are discussed later in this section (e.g., household
coping strategies).
Labor is not the only factor that influences the link between income and productivity. In all
retrieved papers there was not enough information on whether there is a linear relationship
between health and productivity. Therefore, and also because of using conservative values
for productivity loss, we assumed that average productivity gain would equal marginal
Fig 6. Global economic benefit (out-of-pocket payments averted) for IDM NTDs, for the period 2011–2030 (billions I$—International
dollars). Total economic benefit from out-of-pocket payments averted, base case estimates and 2.5th and 97.5th percentiles (billions I$—
international dollars), discounting 3% from 2010.
https://doi.org/10.1371/journal.pntd.0006250.g006
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productivity gain. The lack of information in the literature prevents us from knowing if this
would have under- or overestimated the results.
Household coping strategies, social security, productivity loss of caregivers of people with
IDM-NTDs, and work compensation mechanisms were not included in the calculations. How-
ever, household coping strategies can mediate the effects that an illness of a family member
can have on household finances in several ways; for example, another member might start
working to reduce the loss of household income. However, even if coping strategies are able to
maintain the household income, they may reduce future opportunities for children who sus-
pend their education and start working. [23] The productivity loss due to psychosocial conse-
quences of the diseases (i.e.stigma and discrimination) was also not included, since these types
of sequelae are not included in the GBD study; their omission may have led to an underestima-
tion of the economic benefit.
The basis for the diseases (and their sequelae) included in the GBD study was a set of brief
lay descriptions emphasizing the main functional consequences and symptoms associated
with each health state. For the sake of simplicity, comprehensibility, and feasibility, some
aspects of health states were inevitably omitted in the GBD study, which means that it might
not encompass all disease consequences. [40] For instance, erythema nodosum leprosum, a
complication of leprosy that is known to result in direct costs by affected individuals, was not
included. [98] Inclusion of other health states would lead to a higher estimate of the productiv-
ity loss and OPPs, and consequently, of the economic benefit.
The large differences in the magnitude of the economic gain between the different diseases
and sequelae and the affected countries/regions are a direct consequence of the prevalence of
each disease in each country, the consequences of each sequela, the chosen proxy for income
and the percentages of patients being treated and paying for treatment for these diseases in
each country or region.[34] One should be careful when making comparisons between dis-
eases. First, the results for each disease are affected differently by the data limitations and
potential biases in the methodology mentioned in the ‘Limitations’ section. The estimated eco-
nomic benefit from investments in NTDs also relies on the way productivity is valued in mon-
etary terms. Assigning exclusively monetary value to these domains in terms of productivity
gain undervalues the much bigger gain in physical and mental health that will lead to the
increase in productivity. Therefore, policymaking should consider the health impact of con-
trolling NTDs and not simply the economic benefit (as calculated here).
The expected benefits in 2021–2030 are greater than that in 2011–2020, which is not sur-
prising, since the difference in disease frequency between the counterfactual scenario and tar-
get achievement scenario will be greater in 2021–2030 (after the targets are met).
The gains of achieving the 2020 targets for IDM diseases are not restricted to the economic
benefits, with billions of people gaining physical and mental health, increased mobility,
improved performance in school, access to care, structural improvement of health care ser-
vices, community participation, and democracy with the control/elimination and eradication
of NTDs. [99] Therefore the economic benefits estimated in this study represent just one part
of the benefits that society could experience by achieving the London Declaration goals.
Comparisons with the literature
As far as we are aware of, this is the first reported attempt to estimate the economic burden of
IDM diseases per endemic country and globally, from an individual’s perspective. We know of
only one other global cost-of-illness study of an IDM disease. Specifically, Lee at al. estimated a
global annual burden from Chagas disease of US$ 0.5 ($0.2–1) billion in healthcare costs (cor-
rected to US$2005 values for comparison) and US$ 6 (4–8) billion including lost productivity
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for Latin America related to disease-induced early mortality, using a societal perspective. Their
estimate of healthcare costs is approximately 30% less than our estimate of annual OPPs of US
$ 0.85 (0.1–2.4) billion (2011–2030) while their estimate of lost productivity related to mortal-
ity is two times greater than our annual general productivity loss average of US$ 1.4 (0.9–2.0)
billion using an individual’s perspective. However, it is difficult to make meaningful compari-
sons between our estimates and their estimates because of differences in methodology. For
example, Lee et al grouped countries into quartiles based on GDP per capita (low/low-middle/
high-middle/high income) and estimated the healthcare costs by quartile, assuming a linear
correlation between costs and GDP per capita. With the exception of the three most prevalent
countries (for which we had country-specific estimates), we converted one general Latin
American estimate to local currencies of each of the other endemic countries. Lee et al
included treatment-seeking probability in their model that was much higher than the percent-
age that we used (78% versus 35%). Also, they did not mention what they used regarding per-
centage of people paying for the treatment. [100]
NTDs and poverty
Paying for treatment—especially for IDM-NTDs treatment—can be catastrophic for individu-
als and even for households.[35] This is one of the reasons why the Sustainable Development
Goals (SDGs) are more difficult to achieve without addressing NTDs (and vice-versa). This is
especially true for goal 3.3: ‘By 2030, end the epidemics of AIDS, tuberculosis, malaria and
neglected tropical diseases and combat hepatitis, water-borne diseases and other communica-
ble diseases.’ [7,101] Furthermore, NTDs constitute an obstacle to achieving wider human
development outcomes (for instance, food and nutritional security, and improved maternal
and child health). So, undoubtedly, achieving universal health coverage for NTDs will support
progress in various interdependent development areas, such as poverty, education, sanitation,
nutrition, water and gender equality. [9,70]
Limitations
Prevalent cases. Due to the scarcity of data on NTD spread and control, the prevalence
estimates from the GBD study show very wide confidence intervals. These wide CIs affect the
predictions by De Vlas et al. of the health impact of achieving the targets described in the Lon-
don Declaration. Substantial uncertainty regarding the frequency of IDM diseases also existed,
where the variation ranged from five times less to up to three times greater than the mean val-
ues (Table 7), dependent on availability of country and disease-specific epidemiological data
[26]. This uncertainty only increased as the GBD numbers were extrapolated to estimate the
prevalence in the period of 2010–2030. Given the influence of disease frequency on our esti-
mates of economic impact, we included uncertainty about disease frequency in our sensitivity
analyses. The results of these analyses show that even if the true prevalence values were close
to the lower limits of the ranges used in our analyses, the economic impact would still be
substantial.
Productivity loss and out-of-pocket payments. In general, limited data was found on
productivity loss and out-of-pocket payments, as well as the percentages of patients getting
treatment or having to pay for it. As described in the Methods section, the OPP estimates avail-
able in the literature regarding IDM-NTDs varied, partly because some sources included only
drugs, while others included other medical and non-medical costs. This means that the values
used might have been overestimated for some diseases but underestimated for other diseases.
For instance, the variability in OPP prices for Chagas disease between Argentina and Brazil is
due to their differences regarding the organization of the health system, the approaches to
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treating Chagas disease and its manifestations, and the infrastructure to treat Chagas manifes-
tations. As an example, the digestive form of Chagas disease frequently needs surgery, but the
direct costs related to it depend on access to hospital care and whether treatment is insured.
[38,50–68]
We also assumed that the percentage of patients paying for treatment equals the percentage
of uninsured persons. This could lead to an overestimation of the costs, since not all individu-
als affected by NTDs might want treatment or be able to pay for it. However, it could also be
an underestimation of the costs, since in many countries insured patients pay for treatment
out-of-pocket in order to be treated faster.
When no OPP or productivity loss values could be found, assumptions were made. In some
cases, data from other diseases with similar sequelae were used. For instance, the productivity
loss from disfigurement due to HAT was estimated using the estimate for onchocerciasis mod-
erate scriot disease since they have the same GBD sequela category. [102]
Most of the studies described lost productivity in working days missed because of the dis-
ease sequelae (absenteeism), especially for visceral leishmaniasis and Chagas digestive disease,
where treatment itself requires a long hospitalization.[41–43,88,103–106] Only a few studies
provided quantitative estimates of the decreased productivity loss at work due to presenteeism,
something that can occur because of problems such as disfigurement or the early stages of
Chagas disease.[38,62]
Several assumptions regarding the generalizability of data had to be made due to lack of
data. First, the same estimate for productivity loss was applied to men and women, even
though the degree of productivity loss may differ between the two. [107–112] Secondly, for
each sequela, the same estimate for productivity loss was applied to all individuals and coun-
tries, even though it differs between professions and settings. A similar situation was seen with
OPPs, since sometimes only one estimate for one country was available (i.e. HAT), although
the values used in the different countries were adjusted using CPI and PPP. Transferring the
data from one country to another might have led to over- or underestimates of productivity
loss estimates, as well as OPPs, depending on the disease sequela, the profession and the work-
ing environment, and the characteristics of each health care system.[34,113]
The achievement of 80% essential health services coverage and 100% financial protection
from out-of-pocket payments in 2030, will surely happen in various ways and paces in the
191 countries included in this study. Most countries might want to invest sooner to gain
more efficiency by reducing the vectors and prevalent cases and thereby reducing the num-
ber of infected individuals and disease transmission. This approach would probably follow a
curve of ‘economies of scale’, which would mean more investments than the linear approach
we followed. This would probably result in less economic benefit, but it would be difficult to
estimate how much less, given the many possibilities and scenarios each country faces. In
this sense, we calculated an ideal scenario that included reaching both the London Declara-
tion targets and the WHO/World Bank recommendations for universal coverage and finan-
cial protection regarding NTDs aiming to provide extra arguments in favor of pursuing
them.
Income. Different methods have been used in previous economic analyses of NTDs to
approximate the rural adult wage, including use of GDP per capita, average agricultural
value added per worker and the lowest wage rate from different predefined wage sources.
[25,114,115]
The GDP per capita of the lowest income quintile was used as a proxy for income for our
calculations, since it provided the lowest—and therefore most conservative—estimates possi-
ble without having to combine multiple data sources. This approach could be criticized as an
overestimation of the annual productivity loss of the affected populations, since NTDs are
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typically known as diseases of the poorest. We consequently varied income to the GDP per
capita of the lowest decile in the sensitivity analysis.
Sensitivity analyses
A good estimate of the uncertainty around the economic impact shown in this paper is an
impossible task, since the uncertainty regarding the impact on prevalence over the years can-
not be reliably estimated Although sensitivity analyses were carried out to estimate the degree
of uncertainty surrounding our estimates of economic benefit, greater knowledge of the vari-
ables used would improve the quality of the analyses.
Despite the effort to account for many of the differences between diseases (sequela, produc-
tivity loss, OPP per disease, etc), our analyses represent a simplification of reality. In case more
empirical data become available, more detailed studies could be done for each disease. More-
over, individual countries are encouraged to perform similar analyses to gather and use local
data wherever possible to derive better local estimates of economic benefit.
Reaching the 2020 targets for the 10 London Declaration NTDs described by the WHO
[15,17] will depend on continued and sufficient efforts to achieve them, so especulating that
they will be met of course implies a natural uncertainty about the future. The real economic
benefit will certainly depend on local data, local circumstances, and the degree that each coun-
try will reach those targets. In this sense, our results support the implementation of efforts to
reach these goals, but our results cannot help in deciding on how to reach them.
Conclusions
While the different factors of uncertainty described in the Discussion suggest that the results
of this study should be interpreted with care, we can safely conclude that the economic benefits
to individuals are at least equal to the investments required by governments and their develop-
ment partners to reach the London Declaration 2020 targets. It is more likely that the eco-
nomic benefits will far exceed the necessary investments. Given the higher frequency of NTDs
among the poorest households, these investments represent good value for money in efforts to
increase human well-being and freedom, to better share the world’s prosperity and reduce
inequity. We hope that these results can help policymakers in affected countries to choose to
add NTDs to their public health, medical and scientific priority lists. A concerted effort is
needed to collect better epidemiological and economic data to enable more accurate and com-
plete estimates, which can be a better basis for planning and decision making.
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